Latest / This Is Why with Dr. Busti / TMP-SMX + Spironolactone Drug Interaction: Why Potassium Can Rise

Transcript

TMP-SMX + Spironolactone Drug Interaction: Why Potassium Can Rise · This Is Why with Dr. Busti

• 0:00
  SPEAKER_00: Okay, you're managing an older adult who's taking sperno lactone as part of their chronic treatment for heart failure.
• 0:07
  SPEAKER_00: But then a prescription for trimethoprin sulfamethoxazole is added for a suspected urinary tract infection.
• 0:16
  SPEAKER_00: Now it sounds rather routine, but now two different drug actions are limiting the kidney's ability to regulate a particular electrolyte.
• 0:25
  SPEAKER_00: From an evidence perspective, in observational studies of spermalactone users ages 66 or older, this combination was associated with a higher odds of hospitalization and more than twice the odds of sudden death compared with amoxisone.
• 0:43
  SPEAKER_00: Now those studies don't prove causation, but they identify a signal clinicians should not ignore.
• 0:50
  SPEAKER_00: But the question is, what electrolyte abnormality?
• 0:55
  SPEAKER_00: Why is this a risk?
• 0:56
  SPEAKER_00: And why is it happening?
• 0:58
  SPEAKER_00: And what do we do about it clinically?
• 1:00
  SPEAKER_00: Okay.
• 1:01
  SPEAKER_00: And with that, I'm Dr.
• 1:03
  SPEAKER_00: Busta, your faculty and host on This Is Why, a show that's dedicated to helping healthcare professionals transform their medical knowledge from what to why, because that improves the how.
• 1:17
  SPEAKER_00: We are in the category of drug interactions.
• 1:20
  SPEAKER_00: Okay, my goal is to help us understand these interactions so that we can proactively recognize and manage them in everyday clinical practice.
• 1:30
  SPEAKER_00: So on this episode, we're gonna focus on why trimethoprim sulfamethoxazole, an antimicrobial agent, and sperno lactone, an antagonist to aldosterone, can become a dangerous combination that impacts the electrolyte potassium.
• 1:49
  SPEAKER_00: And who is at great risk?
• 1:51
  SPEAKER_00: And how to approach prevention and the monitoring.
• 1:55
  SPEAKER_00: Okay, now that we know spernolactone is an aldosterone antagonist and more commonly called a minerallocorticoid receptor antagonist, depending on the patient, we may encounter this drug in patients with heart failure, hypertension, you know, edema, andor primary hyperaldosteronism.
• 2:14
  SPEAKER_00: Now, hyperkalemia is already one of that drug's central safety concerns.
• 2:20
  SPEAKER_00: But what about trimethoprone sulfamethoxol?
• 2:23
  SPEAKER_00: You know, it's often known as TMPSMX, and it's a familiar antimicrobial combination that's used in everyday clinical practice.
• 2:32
  SPEAKER_00: But the potassium problem is driven primarily in this situation by trimethoprim or the TMP component.
• 2:41
  SPEAKER_00: Okay, now the real issue is not that one drug raises the concentration of the other.
• 2:47
  SPEAKER_00: It's not primarily a cytochrome P450 mediated interaction like we commonly see in clinical practice.
• 2:54
  SPEAKER_00: Instead, it is a pharmacodynamic convergence at the distal aspect of the nephron.
• 3:04
  SPEAKER_00: Now, I always believe it's important to be oriented to the anatomy.
• 3:08
  SPEAKER_00: And we are in the area just before the collecting duct.
• 3:13
  SPEAKER_00: Okay, now this matters because both drugs interfere with the kidney's ability to eliminate potassium.
• 3:19
  SPEAKER_00: However, they act at different points in that process.
• 3:23
  SPEAKER_00: Now, to understand the interaction, we need to start with the collecting duct principal cells.
• 3:31
  SPEAKER_00: Now, sodium enters through the tubular lumen through the epithelial sodium channel or the enac, ENAC, right?
• 3:44
  SPEAKER_00: The sodium potassium ATPA pump on the other side, the blood-facing side, then moves sodium out of the cell and potassium comes into it.
• 3:58
  SPEAKER_00: Now that sodium movement, okay, follow me here, that sodium movement helps to create an electrical gradient that supports potassium secretion into or back into the tubular lumen for eventual removal.
• 4:15
  SPEAKER_00: Now, when present, okay, aldosterone strengthens this system.
• 4:21
  SPEAKER_00: Now it does so by promoting the machinery, basically turning on the genes that make those proteins and transporters involved in that sodium reabsorption and that potassium secretion.
• 4:36
  SPEAKER_00: So think about it this way sodium reabsorption helps create the conditions that allow potassium to normally leave the body.
• 4:48
  SPEAKER_00: Now, if we weaken that process, urinary potassium excretion can decrease, and thus we set up a mylu that favors the overall retention and accumulation of potassium.
• 5:03
  SPEAKER_00: So why does this happen?
• 5:05
  SPEAKER_00: Let's look at the two mechanisms, one at a time, but in a framework of their, again, pharmacodynamic convergence.
• 5:16
  SPEAKER_00: So we know spironolactone, it provides one of the first hits, especially those patients already on it for heart failure.
• 5:24
  SPEAKER_00: We know that it's an antagonist to that mineralicorticoid receptor.
• 5:29
  SPEAKER_00: And in doing so, it reduces aldosterone-mediated support for that sodium reabsorption and potassium secretion.
• 5:41
  SPEAKER_00: Now, trimethopprim or that TMP component provides the second hit when it's introduced.
• 5:48
  SPEAKER_00: It inhibits that epithelial sodium channel in that distal aspect of the neuron, uh nephron, in a manner that is similar to the potassium-sparing diuretic amyluride.
• 6:03
  SPEAKER_00: Now, less sodium enters through the epithelial sodium channel, the electrical drive for potassium secretion begins to fall, and the kidney retains then more potassium.
• 6:16
  SPEAKER_00: Okay.
• 6:17
  SPEAKER_00: But let's stop there for a quick moment and let's ask the obvious question.
• 6:22
  SPEAKER_00: You know, why does trimethoprim or TMP have this effect?
• 6:27
  SPEAKER_00: It really comes down to, guys, the shared structural features that it has with ameliuride.
• 6:34
  SPEAKER_00: Remember, ameliuride is that potassium-sparing diuretic.
• 6:38
  SPEAKER_00: And you can see that on the chemical structures for both of these drugs.
• 6:45
  SPEAKER_00: The highlighted portions of both drug molecules display that pharmacodynamic convergence where it's happening to create the biologic effect at the cellular level.
• 6:56
  SPEAKER_00: It's a concept also thought of as drug mimicry.
• 7:02
  SPEAKER_00: Now, where shared molecular structures allow for shared receptor binding.
• 7:07
  SPEAKER_00: That's the place that this is happening.
• 7:10
  SPEAKER_00: So if you have an antimicrobial agent being used to treat a UTI that also happens to function like a potassium-sparing diuretic, well, then you obviously create a problem.
• 7:22
  SPEAKER_00: So therefore, one drug reduces the aldosterone signal while the other one partially blocks the sodium channel pathway.
• 7:32
  SPEAKER_00: Different targets, same final problem.
• 7:35
  SPEAKER_00: There's less potassium being excreted into the urine or leaving the body, and the potential then is for the rise in the serum potassium level.
• 7:46
  SPEAKER_00: Now let's transition to the clinical application.
• 7:49
  SPEAKER_00: Who is most vulnerable?
• 7:51
  SPEAKER_00: We need to start with patients who already have limited renal potassium clearance.
• 7:59
  SPEAKER_00: Now that includes patients with impaired renal function, those who have already an existing or baseline elevated potassium level, and other disturbances in potassium homeostasis, rare genetic conditions that we don't commonly see.
• 8:15
  SPEAKER_00: However, the risk can further be manifested with additional, obviously, potassium-raising medications, including potassium supplements, potassium-containing salt substitutes, and other medications that impair potassium elimination, like our angiotensin converting enzyme inhibitors, ACE inhibitors, or angiotensin receptor blockers, ARBs.
• 8:38
  SPEAKER_00: So in this case, trimethhop exposure clearly matters.
• 8:43
  SPEAKER_00: The product labeling also warns that hyperkalemia may occur only, not only with high doses, but with recommended doses in those susceptible patients.
• 8:55
  SPEAKER_00: Now these are warnings that we are, guys, technically responsible for, aren't we?
• 9:01
  SPEAKER_00: Okay, we also need to think about renal function.
• 9:03
  SPEAKER_00: You know, it matters as a result of this because it's handling both potassium and other electrolytes and also influences appropriate drug dosing.
• 9:13
  SPEAKER_00: Now let's consider the clinical signal and the evidence.
• 9:17
  SPEAKER_00: In a population-based study of sperno lactone users ages 66 or older who have received an antibiotic for a UTI like trimethropemulfamethoxazole was associated with an adjusted odds ratio of 12.4 for hospitalization with hyperkelemia compared with the antibiotic amoxicillin.
• 9:43
  SPEAKER_00: The 95% confidence interval was 7.1 to 21.6.
• 9:49
  SPEAKER_00: Now a second study in older spironolactone users found that again trimethoprim sulfamethoxyl was associated with an adjusted odds ratio of 2.46 for sudden death compared with amoxicillin.
• 10:08
  SPEAKER_00: The 95% confidence interval was 1.55 to 3.9.
• 10:13
  SPEAKER_00: So both studies assessed evidence uh events within 14 days of antibiotic exposure.
• 10:23
  SPEAKER_00: Okay.
• 10:24
  SPEAKER_00: Those numbers are concerning, right?
• 10:26
  SPEAKER_00: But we need to interpret them correctly.
• 10:28
  SPEAKER_00: You know, they come from observational studies in older adults.
• 10:32
  SPEAKER_00: An odds ratio is not the same thing as an absolute risk, and and the comparator does matter.
• 10:38
  SPEAKER_00: And the sudden death study could not prove that hyperkelemia caused every death.
• 10:45
  SPEAKER_00: But we know small changes in the potassium can impact cardiac conduction.
• 10:51
  SPEAKER_00: You know, the appropriate conclusion is that the combination of these meds carries a clinically important safety signal.
• 11:00
  SPEAKER_00: Not that every patient will experience that outcome, of course.
• 11:04
  SPEAKER_00: So how do we use this in real-world clinical practice?
• 11:08
  SPEAKER_00: Okay, well, first, recognition should begin before the prescription is finalized and even dispensed.
• 11:15
  SPEAKER_00: And that's why a medication use evaluation or MUE is done or should be done accurately.
• 11:22
  SPEAKER_00: We need to confirm whether spinolactone or some other mineral corticoid receptor antagonist, ACE inhibitor, angiotensinal receptor blocker is being used for that matter, is also active or present.
• 11:36
  SPEAKER_00: So you also want to then review the most recent labs, and particularly what is that potassium level and what is the patient's renal function.
• 11:46
  SPEAKER_00: Look at four other potassium-raising medications, supplements, salt substitutes, and then ask whether that trimethroprom sulfamethoxidol is necessary and or is the best option for the suspected infection, and whether its dose fits the patient's renal function and indication.
• 12:06
  SPEAKER_00: So when that risk of hyperkelemia exists, do not depend solely on the symptoms to identify the problem.
• 12:14
  SPEAKER_00: Why is that?
• 12:15
  SPEAKER_00: Well, because hyperkelemia may be asymptomatic, especially early on.
• 12:20
  SPEAKER_00: When early symptoms occur, they may also be nonspecific.
• 12:24
  SPEAKER_00: And you know, sometimes we just we just dismiss those.
• 12:28
  SPEAKER_00: While severe or later abnormalities can produce conduction changes, dangerous arrhythmias, and now the patient is feeling sometimes even palpitations or getting lightheaded.
• 12:40
  SPEAKER_00: So now it's also relevant to recognize that the approved drug labels support close monitoring and more frequent observation in high-risk settings, but they do not give us any one universal dosing or specific monitoring schedule that we have to do for every patient.
• 13:00
  SPEAKER_00: And this is why understanding the why behind what we do helps us as clinicians decide on the how.
• 13:08
  SPEAKER_00: How are we going to monitor and manage this potential scenario?
• 13:12
  SPEAKER_00: Ideally, before it occurs, but for some of us in the acute care environment, right, sometimes we have to manage it after a hit has already started to manifest and the patient has come in as a result of it.
• 13:23
  SPEAKER_00: Therefore, monitoring should reflect the patient's baseline.
• 13:27
  SPEAKER_00: Potassium, renal function, dose, duration, the interactions of other drugs, and the indication in the clinical setting for which it's being used.
• 13:37
  SPEAKER_00: Now, just as important, someone must own that follow-up.
• 13:42
  SPEAKER_00: Ordering a potassium level without a clear plan to review and act on it is not a safe strategy, is it?
• 13:50
  SPEAKER_00: The first management question is whether the combination can be avoided to begin with.
• 13:55
  SPEAKER_00: If the antimicrobial therapy is needed, well then choose an effective option based on the infection, culture, susceptibility information, allergy history, renal function, the local resistance patterns, and the patient's overall clinical picture.
• 14:12
  SPEAKER_00: For counseling, explain that the interaction may affect potassium when the patient even feels well.
• 14:20
  SPEAKER_00: Ask the patient not to add potassium supplements or potassium-containing salt substitutes, especially if they're being managed for hypertension without checking with their primary care or prescribing provider.
• 14:34
  SPEAKER_00: First, give them clear instructions about laboratory follow-up and when to seek urgent help.
• 14:40
  SPEAKER_00: And avoid telling patients to independently stop essential medications unless that is the treating team's ultimate plan.
• 14:49
  SPEAKER_00: So here are four points to remember for this drug interaction.
• 14:52
  SPEAKER_00: First, trimethoprin is the component, guys, responsible for that amelioride-like effect in the distal nephron.
• 15:02
  SPEAKER_00: Second, sperno lactone and trimethprin act at different points, but both results in a reduction of potassium excretion from the kidneys.
• 15:14
  SPEAKER_00: Third, studies in older spinolactone users identified a strong observational safety signal within 14 days, but those results do not establish absolute risk or causation for every patient.
• 15:30
  SPEAKER_00: And fourth, prevention depends on reviewing the indication kidney function, the baseline potassium, the complete medication list, and who will own the follow-up and monitoring plan.
• 15:42
  SPEAKER_00: That is why a familiar antibiotic can become a high-risk prescription when the patient is already taking Spronolactone.
• 15:51
  SPEAKER_00: You know, if this helped you guys understand the why behind this interaction, please share it with another healthcare professional or your colleagues and feel uh subscribe to the channel and give us the support.
• 16:03
  SPEAKER_00: We really appreciate it.
• 16:04
  SPEAKER_00: And keep learning the why because that improves the how.